Bibliography
- Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997;54(Suppl 4):22-9
- Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997;15:3185-91
- Muggia FM, Safra T, Groshen S, et al. Pegylated liposomal doxorubicin: antitumor activity in epithelial ovarian cancer or cancer of peritoneal origin. Oncology 1997;11(S11):38-44
- Harris JM, Martin NE, Modi M. Pegylation. Clin Pharmacokinet 2001;40:539-51
- Agrawal S. Importance of nucleotide sequence and chemical modification of antisense oligonucleotides. Biochim Biophys Acta 1999;1489(1):53-68
- Zelphati O, Szoka FC Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996;93(21):11493-8
- Rait AS, Pirollo KF, Xiang L, et al. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 2002;8(8):475-86
- Pirollo KF, Zon G, Rait A, et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006;17(1):117-24
- Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995;92(16):7297-301
- Subramaniam V, Vincent IR, Gilakjan M, et al. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol 2007;83(3):332-40
- Buonaguro L, Devito C, Tornesello ML, et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007;25(32):5968-77